Update on AVANIR's Neurodex(TM) New Drug Application

SAN DIEGO--(BUSINESS WIRE)--Aug. 31, 2005--AVANIR Pharmaceuticals (AMEX:AVN) announced that it has been advised by the U.S. Food and Drug Administration (FDA) today that it should not expect a determination on the acceptability, or otherwise, of its New Drug Application (NDA) for Neurodex for the treatment of pseudobulbar affect (PBA) until October 10, 2005. The FDA determined that the receipt date of the filing is to be August 10, 2005, due to supplemental data provided by the Company on that date at the request of the FDA. In the interim, the company anticipates continuing communication with the FDA routinely associated with a NDA.

AVANIR Pharmaceuticals is focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious disease. AVANIR has initiated a Phase 3 clinical trial of Neurodex for the treatment of diabetic neuropathic pain. AVANIR has active collaborations with two international pharmaceutical companies, Novartis, for the treatment of inflammatory disease, and AstraZeneca, for the treatment of cardiovascular disease. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

Statements in this press release that are not historical facts, including statements that are preceded by, followed by, or that include such words as "estimate", "anticipate", "believe", "plan", or "expect", or similar statements are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results expressed or implied by such statements. There can be no assurance that AVANIR's New Drug Application for Neurodex(TM) will be accepted for filing by the FDA within the anticipated time period or at all; that Neurodex will receive regulatory approval; or that even if such regulatory approval is received, AVANIR will be able to market Neurodex successfully. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are often unpredictable and outside the influence and/or control of the company. Risks and uncertainties also include the risks set forth in AVANIR's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and from time-to-time in other publicly available information regarding the Company. Copies of this information are available from AVANIR upon request. AVANIR disclaims any intent or obligation to update these forward-looking statements.


    CONTACT: AVANIR Pharmaceuticals
             Patrice Saxon, 858-622-5202
             psaxon@avanir.com
             or
             FischerHealth Life Sciences
             Aline Schimmel, 212-601-8278
             aschimmel@fischerhealth.com

    SOURCE: AVANIR Pharmaceuticals